RPRX
Royalty Pharma Plc
57.70$
-1.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 0.0% | 0.0% | 2.1% | 7.6% | 56.2% | 10.9% | 19.8% | 40.4% | 23.8% | 32.4% | 0.2% | |
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 6.0% | 4.8% | 7.4% | 21.9% | 4.6% | 1.2% | 8.7% | 7.9% | 2.2% | 0.1% | 19.0% | |
| – | 1.8% | 0.9% | 6.7% | 3.4% | 5.7% | 8.6% | 8.0% | 10.2% | 10.6% | 10.5% | 24.1% | |
| – | 47.8% | 57.9% | 41.2% | 24.0% | -44.6% | 24.8% | 37.5% | 86.3% | 36.6% | 42.9% | 34.4% | |
| – | 48.1% | 38.5% | 58.8% | 76.0% | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% | |
| – | 13.6% | 12.7% | 15.5% | 15.6% | 14.8% | 7.4% | 7.3% | 8.4% | 7.9% | 10.0% | 12.9% | |
| – | 45.9% | 40.6% | 84.1% | 84.6% | 135.7% | 80.2% | 54.2% | 10.3% | 72.2% | 58.8% | 55.7% | |
| – | 10.7% | 10.4% | 34.0% | 24.1% | 19.3% | 54.0% | 33.3% | 8.4% | 24.0% | 20.9% | 23.3% | |
| – | 35.2% | 30.1% | 75.7% | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% | |
| – | 52.2% | 56.9% | 101.6% | 102.0% | 151.8% | 88.7% | 62.5% | 18.9% | 80.2% | 68.8% | 68.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.